Individual applications of clopidogrel after Percutaneous coronary intervention

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001807

Enrollment

Unknown

Registered

2011-12-11

Start date

2011-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease

Interventions

1:According CYP2c19 genotype of antiplatelet therapy

2:Clopidogrel 75mg / d

Eligibility

Sex/Gender

All

Age

30 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age <75 years of age; 2. patients who were diagnosed coronary heart disease by coronary angiography and who would underwent PCI; 3. application without clopidogrel contraindications; 4. patients with informed consent.

Exclusion criteria

Exclusion criteria: 1. clopidogrel contraindications exist; 2. after treatment blood pressure was still> 180/100mmHg; 3. platelets <100*10^9/L, neutrophils <1.8*10^9/L; 4. the risk of serious bleeding; 5. to accept Ticlid, double-ethyl of membrane platelet glycoprotein IIb/IIIa inhibitor therapy in the last 7 days or within 6 hours of these drugs may be applicate; 6. cancer; 7. NYHA IV stage of heart failure.

Design outcomes

Primary

Measure	Time frame
Platelet aggregation;incidence of bleeding;Cardiac events;Rate of rehospitalization;	—

Countries

China

Contacts

Public ContactMA Yi-tong

myt-xj@163.com+86 0991 4366169

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 23, 2026